Four years ago, in December 2013, I highlighted Atlas’ seed-led venture creation model by walking through our Fund IX Seed Class of 2013.  Only a short 1400 days ago, reading it again last week made it seem like an eternity.

This blog was written by Mike Gilman, CEO of Obsidian Therapeutics and Atlas Advisor, as part of the From The Trenches feature of LifeSciVC. Consider the leech – the first living medicine. In its heyday in the 19th century –

It’s been an exciting year for new drug approvals, with the FDA on a similar pace to the gangbuster year of 2015. Many of these new medicines address significant and meaningful needs, or offer additional therapeutic choices for patients and

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. On June 27, 2016 England’s soccer team was knocked out of the European Championships by Iceland – a tiny

Back in the summer, I got the call that no biotech venture investor wants to get. On the morning of August 8th, I received an urgent text of “can you talk now?” quickly followed with a call. I learned then

The field of gene and cell therapy has witnessed an unprecedented few months, almost unimaginable only a few years ago. It’s worth pausing to reflect on some of the recent highlights: FDA approval of two chimeric antigen receptor (CAR) T-cell

The term “undruggable” has entered common industry vernacular over the past two decades to describe biologic targets that couldn’t be addressed via narrow conventional pharmacologies involving catalytic-site inhibitors and antibodies. The “druggable genome” historically included intracellular catalytic proteins, (e.g., enzymes

This blog was written by Sam Truex, former CBO of Padlock and Synlogics, and current Atlas EIR, as part of the From the Trenches feature of LifeSciVC. Funding for biotech companies has been abundant this year. As covered the first

This blog was written by Jason Gardner, CEO and co-founder of Magenta Therapeutics, as part of the From The Trenches feature of LifeSciVC.            There’s a proverb that goes like this, “If you want to go

We’re excited to announce the launch of Science2Startup, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities. This event is in many ways a relaunch of the successful URES (University Research

Today Nimbus and Celgene announced a significant partnership focused on autoimmune and inflammatory diseases. The alliance includes two pre-clinical autoimmune-focused programs in various stages of drug discovery. The most advanced program is a highly selective inhibitor of Tyk2, an immunokinase

Private biotech funding numbers are in for the third quarter and on an absolute capital basis they are huge: $3.6B flowed into private biotechs, the largest quarter of VC-funding into biopharma ever in the history of our industry, according to